The spy who drugged me


In the early 1950s, the Soviet Union put a double agent on trial. Observers from the US, including CIA personnel, noticed that the agent was under the influence of a strong drug. This is said to have kicked off a wave of experimentation with mind-altering drugs by the agency, with civilians in the US and Canada serving as unwitting test subjects. There were several such operations with codenames like Bluebird and Midnight Climax. One of the objectives of Operation Bluebird was to evaluate whether accurate information could be obtained from willing or unwilling individuals . Operation Artichoke, Bluebird's successor, wanted to "get control of an individual to the point where he will do our bidding against his will and even against such fundamental laws of nature such as self-preservation ." Operation Midnight Climax, on the other hand, involved young women who lured men to hideaways in New York and San Francisco and fed them LSD or marijuana, while other men watched the action through two-way mirrors and taperecorded the sounds.

The New Yorker profiles Colonel James Ketchum, one of the scientists involved in the US psychochemical program at Edgewood Arsenal. At Edgewood, volunteers were routinely fed cocktails of drugs, from LSD to sarin nerve gas. One subject, who had been exposed to sarin gas a week earlier, was handed a glass of whiskey laced with 20 milligrams of the drug PCP. He passed out, and began breathing in a pattern associated with neurological trauma or cardiac stress. Ketchum maintained detailed records, and is now expected to be the star witness in a class action lawsuit against the US government brought on by the volunteers who, in several cases, have had their lives or sanity ruined by these experiments.

Yahoo to sell 'medical test kits' to detect genetic risks


Yahoo to sell 'medical test kits' to detect genetic risks
Internet firm Yahoo has planned to sell a medical test kit in Japan, with the aim to help individuals identify their genetic risk for contracting various diseases.
TOKYO: Internet firm Yahoo has planned to sell a medical test kit in Japan, with the aim to help individuals identify their genetic risk for contracting various diseases.
The test kit, which is priced at 29,800 Yen was developed by Tokyo-based genetic analysis specialist Genesis Healthcare Co.
Yahoo Japan, which is set to sell the kit from December, projects sales of 300 units a month, the Japan Times reports.
According to the report, using the kit, consumers are directed to send saliva samples to Genesis Healthcare, which will analyze 68 genes and report back any genetic predispositions to certain ailments, such as stroke or gout.
The firm will also advise customers on lifestyle changes that would reduce their risk of developing diseases they are genetically susceptible to, the report said.

Computer predicts sudden cardiac death risks


Computer predicts sudden cardiac death risks
A computer model predicted the risk of irregular heartbeats and sudden cardiac death, making possible more complex cardiac models to calculate the consequences of genetic, lifestyle and other changes to the heart.
WASHIGTON: A computer model predicted the risk of irregular heartbeats and sudden cardiac death, making possible more complex cardiac models to calculate the consequences of genetic, lifestyle and other changes to the heart.

"This is a strong proof-of-principle study showing that computer simulation can be used to predict risk of cardiac arrhythmias (erratic beats)," said Coeli M Lopes, assistant professor at the Aab Cardiovascular Research Institute, University of Rochester Medical Centre, who led the study.

Researchers plan on using IBM's supercomputer, the Blue Gene/Q, to develop a model of the whole human heart, the Journal of the American College of Cardiology reports.

With this study under their belts, the research team, including several scientists from the Medical Centre, the IBM TJ Watson Research Center in Yorktown Heights, New York, and the IBM Research Collaboratory for Life Sciences in Melbourne, Australia, is pursuing a much more sophisticated model of the whole human heart.

They plan to predict the effects of new drugs on the electrical activity of the heart -- one of the most challenging hurdles in the development of new drugs and an extremely important part of keeping potentially dangerous drugs off the market, according to a Rochester statement.

The computer model, designed by IBM scientists Matthias Reumann and J Jeremy Rice, includes 192 heart cells made to function electrically like the ventricle wall by assigning varying properties to cells based on their position -- inside, middle, or outside -- in the heart wall.

IBM scientists used canine cardiac cells as a guide, adapting the model cells to act more like ours based on extensive data on the electrical properties of the human heart. In the end, the simulation requires the solution of more than 100,000 complex mathematical equations at least 1,000 times over just to simulate a single heartbeat.

The team turned to more than 600 patients with Long QT syndrome type 1, an inherited disorder that puts patients at greater risk of arrhythmias and sudden cardiac death - to help test the model. Patients were drawn from the US, Japan, the Netherlands, Denmark and Sweden.